	US 12,128,022 B2
	Neutral pH compositions of docetaxel and human serum albumin
Qun Sun, Princeton, NJ (US)
Assigned to Zhuhai Beihai Biotech Co., Ltd., Zhuhai (CN)
Filed by Zhuhai Beihai Biotech Co., Ltd., Zhuhai (CN)
Filed on Jul. 18, 2022, as Appl. No. 17/867,495.
Application 17/867,495 is a continuation of application No. 16/345,615, granted, now 11,419,842, previously published as PCT/US2017/058697, filed on Oct. 27, 2017.
Claims priority of provisional application 62/420,397, filed on Nov. 10, 2016.
Claims priority of provisional application 62/413,603, filed on Oct. 27, 2016.
Prior Publication US 2022/0370399 A1, Nov. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/337 (2006.01); A61K 9/08 (2006.01); A61K 38/38 (2006.01); A61K 47/42 (2017.01); A61K 47/64 (2017.01)

CPC A61K 31/337 (2013.01) [A61K 9/08 (2013.01); A61K 38/385 (2013.01); A61K 47/42 (2013.01); A61K 47/643 (2017.08)]

11 Claims

1. A pharmaceutical composition comprising a non-covalently bound complex comprising Docetaxel and human serum albumin, wherein the composition is a solid formulation, wherein the molar ratio of Docetaxel and the human serum albumin in the composition is from about 0.1:1 to about 5:1, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, wherein the docetaxel concentration in the solution is higher than aqueous solubility of docetaxel, wherein the human serum albumin in the composition is from commercial pharmaceutical human serum albumin solution for infusion, and wherein pH of the composition is from about 5 to about 8.